AtCor Medical

AtCor Medical today announced that a University of Illinois Medical Center, Chicago study1 has highlighted an important new inpatient use for SphygmoCor: monitoring the effects of drug therapy in hospitalised patients with pre-eclampsia, a potentially life-threatening complication of pregnancy.

Please click here to view the ASX/media release

Central BP a Superior Determinant of Left Ventricular Hypertrophy -- New Study Highlights Importance of Central Pressure in Patient Care and Clinical Trials

02 February 2010

AtCor Medical today announced a new National Institutes of Health (NIH)-funded study, published in the Journal of Hypertension, has found that central (aortic) blood pressure, measured noninvasively, is a more important indicator of the development of left ventricular hypertrophy (LVH) than is brachial blood pressure. LVH relates to muscle thickening in the heart’s pumping chamber. Its incidence increases with age and is more common in people who have high blood pressure.

Please click here to view the ASX/media release

1st Half Market Update

28 January 2010

AtCor Medical today announced unaudited H1 FY2010 sales of $4.4 million, a 13% decline in constant currency terms from the record H1 sales in FY2009. This figure does not include a large pharma order that had been expected in December and is now expected to close within the next 30 days. Without this delay the business would have reported positive growth for the half in constant currency. Non-pharma sales for the half grew 17% pcp in constant currency.

Please click here to view the ASX/media release

Second Quarter Report - Appendix 4C

28 January 2010

AtCor Medical today released its quarterly cash flow report for the period ending 30 December 2009.

Please click here to view the ASX/media release